Biodexa Pharmaceuticals (BDRX) has released an update.
Biodexa Pharmaceuticals PLC faces potential delisting from the Nasdaq Capital Market due to its stock price being below the required $1.00 threshold for 30 consecutive business days. The company plans to appeal this decision by requesting a hearing before the Nasdaq Hearings Panel, which will delay any suspension or delisting action. Biodexa is known for its innovative clinical-stage pipeline targeting diseases with unmet medical needs, including treatments for cancer and diabetes.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
